XTX Topco’s Kalaris Therapeutics KLRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$42.6K Buy
+14,726
New +$57K ﹤0.01% 3562
2026
Q1
– Sell
-10,897
Closed -$92K – 4559
2025
Q4
$92K Buy
+10,897
New +$69.7K ﹤0.01% 2659
2025
Q3
– Sell
-24,234
Closed -$64.7K – 3485
2025
Q2
$64.7K Buy
+24,234
New +$109K ﹤0.01% 1970
2024
Q4
– Sell
-1,153
Closed -$21.4K – 3066
2024
Q3
$21.4K Sell
1,153
-901
-44% -$15.8K ﹤0.01% 1834
2024
Q2
$34.2K Buy
2,054
+34
+2% +$600 ﹤0.01% 1549
2024
Q1
$35.1K Sell
2,020
-363
-15% -$5.92K ﹤0.01% 1531
2023
Q4
$37.3K Sell
2,383
-1,271
-35% -$50.1K 0.01% 1283
2023
Q3
$181K Buy
+3,654
New +$249K 0.03% 1050
2023
Q2
– Sell
-848
Closed -$76.9K – 1923
2023
Q1
$76.9K Sell
848
-1,475
-63% -$188K 0.02% 1128
2022
Q4
$274K Buy
2,323
+1,627
+234% +$276K 0.06% 646
2022
Q3
$126K Buy
696
+139
+25% +$21.7K 0.03% 902
2022
Q2
$50K Buy
+557
New +$58.4K 0.02% 744

Other funds holding KLRS

XTX Topco's KLRS Position: Q3 2026 in Review

XTX Topco opened a new position in Kalaris Therapeutics (KLRS) in Q3 2026: 14,726 shares worth $42.6K. The stake represents ﹤0.01% of the portfolio and ranks #3562 among its holdings. This is a return to the name: XTX Topco previously reported a position in KLRS as recently as Q4 2025.

XTX Topco first reported a position in KLRS in Q2 2022 and has held it in 12 quarters since. The position peaked at $274K in Q4 2022. 54 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • XTX Topco held 14,726 shares of Kalaris Therapeutics worth $42.6K as of Q3 2026.
  • Kalaris Therapeutics was a new XTX Topco position in Q3 2026.
  • Kalaris Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q3 2026, its #3562 holding.
  • XTX Topco first reported a position in Kalaris Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • XTX Topco's Kalaris Therapeutics position peaked at $274K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on XTX Topco's 13F filing for Q3 2026, filed 16 Nov 2026.